Latest Manufacturing Capacity News

Page 2 of 22
Pure Foods Tasmania has reported a deeper FY26 loss, negative cash and a material uncertainty over its ability to continue as a going concern. The company says existing facilities may be insufficient from February 2027, with further equity funding uncommitted and a second bank covenant breach possible.
Victor Sage
Victor Sage
27 Oct 2026
Star Combo Pharma has completed a manufacturing expansion that doubles production capacity, but FY2026 revenue fell 15% and profit before tax dropped to $528,472. The company remains cash-backed and dividend-paying, while its next test is converting spare capacity into stronger OEM and Own Brands growth.
Ada Torres
Ada Torres
23 Oct 2026
AML3D has carried $16.8 million of orders into FY27, with its US defence expansion driving a sales pipeline above $80 million. Customer receipts rose 19% in the September quarter, while the company retained $24.42 million in cash to fund capacity expansion.
Victor Sage
Victor Sage
23 Oct 2026
Energy Technologies has outlined two signed commercial arrangements for its Cogenic laser display technology, including a SYNCH purchasing framework worth up to US$10 million and a 5% royalty licence with Amalgamated Vision. The opportunity is meaningful, but the SYNCH arrangement carries no minimum order commitment and still depends on product specifications, acceptance and purchase orders.
Sophie Babbage
Sophie Babbage
22 Oct 2026
Orthocell’s flagship Remplir nerve-repair product gained ground in the US and Thailand during the September quarter, even as total revenue slipped from the June period. The company reported A$39 million in available funds and said it does not currently expect to raise additional capital.
Ada Torres
Ada Torres
22 Oct 2026
Titomic has secured approval for a US$10.3 million direct loan from the US Export-Import Bank to fund a high-pressure cold-spray production cell in Huntsville, Alabama. The project is expected to expand US manufacturing capacity and support at least dozens of full-time jobs.
Victor Sage
Victor Sage
22 Oct 2026
BLS Pharmaceuticals has started FY27 with its strongest quarter on record, reporting A$26.7 million in unaudited revenue and positive operating cash flow. The company reaffirmed its A$105 million to A$115 million revenue guidance while continuing to invest in Australian and Scottish manufacturing capacity.
Victor Sage
Victor Sage
21 Oct 2026
BLS Pharmaceuticals has opened FY27 with record quarterly revenue, positive operating cash flow and reaffirmed full-year guidance. The report contains conflicting Q1 revenue figures of $26.7 million and $27.5 million, while its Scotland expansion remains subject to regulatory approval.
Victor Sage
Victor Sage
15 Oct 2026
DGL Group’s FY26 annual report lays bare a difficult year: revenue and underlying earnings fell, statutory losses widened and the auditor issued a qualified opinion over opening inventory. Management is betting on cost cuts, fuller facilities and a new liquid waste plant to repair performance in FY27.
Victor Sage
Victor Sage
9 Oct 2026
Clarity Pharmaceuticals is approaching pivotal Phase III readouts for its prostate cancer imaging agent, backed by AUD178.3 million in liquid assets. The radiopharmaceutical developer remains deeply loss-making, but expanded manufacturing capacity and early clinical signals are pulling its commercial ambitions into sharper focus.
Victor Sage
Victor Sage
30 Sept 2026
KTEK Aerosystems has restarted deliveries under its principal production program, with an initial batch ready for collection from its European manufacturing network. The company has also lifted stated monthly manufacturing capacity to 200 units, although future revenue remains dependent on output, acceptance and logistics.
Victor Sage
Victor Sage
30 Sept 2026
Firebrick Pharma has approved a phased push into US retail pharmacies after Nasodine online sales grew by more than 200% in FY26. Up to six regional pharmacy groups representing about 700 stores have expressed strong interest in early orders, although no binding orders have been disclosed.
Ada Torres
Ada Torres
29 Sept 2026

Browse the archive

Full archive